How many stocks are there of Regenxbio?
The current number of stocks of Regenxbio is 43.73 M undefined.
Regenxbio Stocks 2024
Regenxbio Stocks
43.73 M
Ticker
RGNX
ISIN
US75901B1070
WKN
A140E0
In 2024, Regenxbio had 43.73 M outstanding stocks, a 0% change from the 43.73 M stocks in the previous year.
The Regenxbio Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2029e | 43.73 |
| 2028e | 43.73 |
| 2027e | 43.73 |
| 2026e | 43.73 |
| 2025e | 43.73 |
| 2024e | 43.73 |
| 2023 | 43.73 |
| 2022 | 43.2 |
| 2021 | 43.9 |
| 2020 | 37.3 |
| 2019 | 36.7 |
| 2018 | 36.6 |
| 2017 | 29.9 |
| 2016 | 26.4 |
| 2015 | 25.4 |
| 2014 | 25.4 |
| 2013 | 25.4 |
Regenxbio shares outstanding US75901B1070 · A140E0
The number of shares was Regenxbio in 2023 — This indicates how many shares 43.734 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Regenxbio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Regenxbio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Regenxbio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Regenxbio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2013 | 25.4 M Aktien |
| 2014 | 25.4 M Aktien |
| 2015 | 25.4 M Aktien |
| 2016 | 26.4 M Aktien |
| 2017 | 29.9 M Aktien |
| 2018 | 36.6 M Aktien |
| 2019 | 36.7 M Aktien |
| 2020 | 37.3 M Aktien |
| 2021 | 43.9 M Aktien |
| 2022 | 43.2 M Aktien |
| 2023 | 43.73 M Aktien |
| 2024e | 43.73 M Aktien |
| 2025e | 43.73 M Aktien |
| 2026e | 43.73 M Aktien |
| 2027e | 43.73 M Aktien |
| 2028e | 43.73 M Aktien |
| 2029e | 43.73 M Aktien |
Regenxbio Aktienanalyse
What does Regenxbio do?
Regenxbio Inc is a biopharmaceutical company that specializes in the development of AAV-based gene therapies for rare genetic diseases. The company was founded in 2009 in Maryland, USA and has since developed an impressive portfolio of therapy options. The history of Regenxbio Inc begins with the realization that gene therapies offer a promising way to treat rare genetic diseases for which there are currently no cures. However, at that time, there were still many technical and regulatory hurdles to overcome. Regenxbio took on these challenges and specialized in the development of adeno-associated viruses (AAV) as vectors for the transfer of therapeutic genes, as these viruses are ideally suited for this purpose. The business model of Regenxbio Inc is based on licensing its technology platform to other companies, which can then develop their own gene therapies. The company has already formed partnerships with major pharmaceutical companies such as AstraZeneca and Novartis, who utilize Regenxbio's technology platform to develop new therapy options for rare diseases. A significant aspect of Regenxbio Inc is the discovery and development of gene therapies for rare diseases. These include diseases such as choroideremia syndrome and mucopolysaccharidosis type I, among others. The company has already conducted clinical trials that have shown promising results and has received approval in the EU. Regenxbio aims to replace invasive and complicated treatments with gene therapy options. Additionally, Regenxbio Inc also offers services in the manufacturing of AAV-based gene therapies. The company supports other firms in the production and quality control of AAV vectors required for the manufacturing of gene therapies. This business sector plays a crucial role in the distribution of therapies to the market. The ultimate goal of Regenxbio Inc is to improve the quality of life for individuals suffering from rare genetic diseases through the development and commercialization of gene therapies. With innovative technologies and partnerships with other pharmaceutical companies, the company has already established an important role in the field of gene therapy development. Overall, the company has a very positive future outlook and will remain under observation in the healthcare industry. Regenxbio ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Regenxbio's Shares Outstanding
Regenxbio's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Regenxbio’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Regenxbio’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Regenxbio’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Regenxbio stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Regenxbio are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Regenxbio evolved in recent years?
The number of shares of Regenxbio has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Regenxbio as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Regenxbio?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Regenxbio pay?
Over the past 12 months, Regenxbio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Regenxbio is expected to pay a dividend of 0 USD.
What is the dividend yield of Regenxbio?
The current dividend yield of Regenxbio is .
When does Regenxbio pay dividends?
Regenxbio pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Regenxbio?
Regenxbio paid dividends every year for the past 0 years.
What is the dividend of Regenxbio?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Regenxbio located?
Regenxbio is assigned to the 'Health' sector.
Wann musste ich die Aktien von Regenxbio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Regenxbio from 11/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.
When did Regenxbio pay the last dividend?
The last dividend was paid out on 11/9/2024.
What was the dividend of Regenxbio in the year 2023?
In the year 2023, Regenxbio distributed 0 USD as dividends.
In which currency does Regenxbio pay out the dividend?
The dividends of Regenxbio are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Regenxbio
Our stock analysis for Regenxbio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Regenxbio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
